Odd sibling: Features of β3-adrenoceptor pharmacology

Molecular Pharmacology

Volumn 86, Issue 5, 2014, Pages 479-484

  Cernecka, Hana ^a   Sand, Carsten ^b   Michel, Martin C ^c  

^a UNIVERSITY OF GRONINGEN   (Netherlands)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL]PHENOXYACETIC ACID; BETA 3 ADRENERGIC RECEPTOR; BETA 3 ADRENERGIC RECEPTOR BLOCKING AGENT; BETA 3 ADRENERGIC RECEPTOR STIMULATING AGENT; MESSENGER RNA; NADOLOL; PROPRANOLOL; LIGAND;

ARTICLE; DESENSITIZATION; DRUG BINDING SITE; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; GENE EXPRESSION; GENETIC POLYMORPHISM; HUMAN; LIGAND BINDING; MOLECULAR RECOGNITION; NONHUMAN; PHOSPHORYLATION; PRIMATE; RODENT; ANIMAL; BINDING SITE; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

ADRENERGIC BETA-3 RECEPTOR AGONISTS; ADRENERGIC BETA-3 RECEPTOR ANTAGONISTS; ANIMALS; BINDING SITES; GENE EXPRESSION REGULATION; HUMANS; LIGANDS; POLYMORPHISM, GENETIC; RECEPTORS, ADRENERGIC, BETA-3;

EID: 84907433555     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.114.092817     Document Type: Article

References (67)

1. Abrams P, Kelleher C, Staskin D, Rechberger T, Kay R, Martina R, Newgreen D, Paireddy A, van Maanen R, and Ridder A (2014) Combination treatment with mirabegron and solifenacin in patients with overactive bladder: efficacy and safety results from a randomised, double-blind, dose-ranging, phase 2 study (Symphony). Eur Urol DOI: 10.1016/j.eururo.2014.02.012 [published ahead of print].
2. Atef N, Lafontan M, Doublé A, Hélary C, Ktorza A, and Pénicaud L (1996) A specific β3-adrenoceptor agonist induces increased pancreatic islet blood flow and insulin secretion in rats. Eur J Pharmacol 298:287-292.
3. Baker JG (2005) The selectivity of b-adrenoceptor antagonists at the human b1, b2 and b3 adrenoceptors. Br J Pharmacol 144:317-322.
4. Baker JG (2010) The selectivity of b-adrenoceptor agonists at human β1-, β2- and β3-adrenoceptors. Br J Pharmacol 160:1048-1061.
5. Bardou M, Rouget C, Breuiller-Fouché M, Loustalot C, Naline E, Sagot P, Frydman R, Morcillo EJ, Advenier C, and Leroy M-J et al. (2007) Is the beta3-adrenoceptor (ADRB3) a potential target for uterorelaxant drugs? BMC Pregnancy Childbirth 7 (Suppl 1):S14.
6. Bengtsson T, Redegren K, Strosberg AD, Nedergaard J, and Cannon B (1996) Downregulation of β3 adrenoreceptor gene expression in brown fat cells is transient and recovery is dependent upon a short-lived protein factor. J Biol Chem271:33366-33375.
7. Berkowitz DE, Nardone NA, Smiley RM, Price DT, Kreutter DK, Fremeau RT, and Schwinn DA (1995) Distribution of β3-adrenoceptor mRNA in human tissues. Eur J Pharmacol 289:223-228.
8. Blin N, Camoin L, Maigret B, and Strosberg AD (1993) Structural and conformational features determining selective signal transduction in the β3-adrenergic receptor. Mol Pharmacol 44:1094-1104.
9. Bylund DB, Eikenberg DC, Hieble JP, Langer SZ, Lefkowitz RJ, Minneman KP, Molinoff PB, Ruffolo RR, Jr, and Trendelenburg U (1994) International union of pharmacology nomenclature of adrenoceptors. Pharmacol Rev 46:121-136.
10. Candelore MR, Deng L, Tota L, Guan X-M, Amend A, Liu Y, Newbold R, Cascieri MA, and Weber AE (1999) Potent and selective human β(3)-adrenergic receptor antagonists. J Pharmacol Exp Ther 290:649-655.
11. Candelore MR, Deng L, Tota LM, Kelly LJ, Cascieri MA, and Strader CD (1996) Pharmacological characterization of a recently described human β3-adrenergic receptor mutant. Endocrinology 137:2638-2641.
12. Carpéné C, Galitzky J, Collon P, Esclapez F, Dauzats M, and Lafontan M (1993) Desensitization of beta-1 and beta-2, but not beta-3, adrenoceptor-mediated lipolytic responses of adipocytes after long-term norepinephrine infusion. J Pharmacol Exp Ther 265:237-247.
13. Cernecka H, Ochodnicky P, Lamers WH, and Michel MC (2012) Specificity evaluation of antibodies against human β3-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 385:875-882.
14. Chambers J, Park J, Cronk D, Chapman C, Kennedy FR, Wilson S, and Milligan G (1994) β3-adrenoceptor agonist-induced down-regulation of Gs a and functional desensitization in a Chinese hamster ovary cell line expressing a β3-adrenoceptor refractory to down-regulation. Biochem J 303:973-978.
15. Chapple CR, Cardozo L, Nitti VW, Siddiqui E, and Michel MC (2014) Mirabegron in overactive bladder: a review of efficacy, safety, and tolerability. Neurourol Urodyn 33:17-30.
16. Chaudhry A and Granneman JG (1994) Influence of cell type upon the desensitization of the β3-adrenergic receptor. J Pharmacol Exp Ther 271:1253-1258.
17. Clément K, Vaisse C, Manning BS, Basdevant A, Guy-Grand B, Ruiz J, Silver KD, Shuldiner AR, Froguel P, and Strosberg AD (1995) Genetic variation in the β3- adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med 333:352-354.
18. Curran PK and Fishman PH (1996) Endogenous β3- but not b 1-adrenergic receptors are resistant to agonist-mediated regulation in human SK-N-MC neurotumor cells. Cell Signal 8:355-364.
19. Dale PR, Cernecka H, Schmidt M, Dowling MR, Charlton SJ, Pieper MP, and Michel MC (2014) The pharmacological rationale for combining muscarinic receptor antagonists and b-adrenoceptor agonists in the treatment of airway and bladder disease. Curr Opin Pharmacol 16C:31-42.
20. Emorine LJ, Marullo S, Briend-Sutren MM, Patey G, Tate K, Delavier-Klutchko C, and Strosberg AD (1989) Molecular characterization of the human β3-adrenergic receptor. Science 245:1118-1121.
21. Engelhardt S and Ahles A (2014) Polymorphic variants of adrenoceptors: physiology, pharmacology and role in disease. Pharmacol Rev (in press).
22. Frazier EP, Michel-Reher MB, van Loenen P, Sand C, Schneider T, Peters SLM, and Michel MC (2011) Lack of evidence that nebivolol is a β3-adrenoceptor agonist. Eur J Pharmacol 654:86-91.
23. Gericke A, Böhmer T, and Michel MC (2013) β3-adrenoceptors: a drug target in ophthalmology? Naunyn Schmiedebergs Arch Pharmacol 386:265-267.
24. Granneman JG and Lahners KN (1992) Differential adrenergic regulation of β1- and β3-adrenoreceptor messenger ribonucleic acids in adipose tissues. Endocrinology 130:109-114.
25. Hatanaka T, Ukai M, Watanabe M, Someya A, Ohtake A, Suzuki M, Ueshima K, Sato S, and Masuda N (2013) Pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in cynomolgus monkeys. Naunyn Schmiedebergs Arch Pharmacol 386:1001-1008.
26. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, and Klotz K-N (2004) Comparative pharmacology of human b-adrenergic receptor subtypes-characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 369:151-159.
27. Horinouchi T and Koike K (2001) Agonist activity of SR59230A at atypical betaadrenoceptors in guinea pig gastric fundus and duodenum. Eur J Pharmacol 416:165-168
28. Hutchinson DS, Evans BA, and Summers RJ (2000) β(3)-adrenoceptor regulation and relaxation responses in mouse ileum. Br J Pharmacol 129:1251-1259.
29. Hutchinson DS, Sato M, Evans BA, Christopoulos A, and Summers RJ (2005) Evidence for pleiotropic signaling at the mouse β3-adrenoceptor revealed by SR59230A [3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate]. J Pharmacol Exp Ther 312:1064-1074.
30. Igawa Y and Michel MC (2013) Pharmacological profile of β3-adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn Schmiedebergs Arch Pharmacol 386:177-183.
31. Igawa Y, Schneider T, Yamazaki Y, Tatemichi S, Homma Y, Nishizawa O, and Michel MC (2012) Functional investigation of b-adrenoceptors in human isolated detrusor focusing on the novel selective β3-adrenoceptor agonist KUC-7322. Naunyn Schmiedebergs Arch Pharmacol 385:759-767.
32. Igawa Y, Yamazaki Y, Takeda H, Akahane M, Ajisawa Y, Yoneyama T, and Nishizawa O (1998) Possible β3-adrenoceptor-mediated relaxation of the human detrusor. Acta Physiol Scand 164:117-118.
33. Liggett SB (1992) Functional properties of the rat and human β3-adrenergic receptors: differential agonist activation of recombinant receptors in Chinese hamster ovary cells. Mol Pharmacol 42:634-637.
34. Liggett SB, Freedman NJ, Schwinn DA, and Lefkowitz RJ (1993) Structural basis for receptor subtype-specific regulation revealed by a chimeric β3/β2-adrenergic receptor. Proc Natl Acad Sci USA 90:3665-3669.
35. Maruyama I, Tatemichi S, Goi Y,Maruyama K, Hoyano Y, Yamazaki Y, and Kusama H (2012) Effects of ritobegron (KUC-7483), a novel selective β3-adrenoceptor agonist, on bladder function in cynomolgus monkey. J Pharmacol Exp Ther 342:163-168.
36. Michel MC (2014) Do β-adrenoceptor agonists induce homologous or heterologous desensitization in rat urinary bladder? Naunyn Schmiedebergs Arch Pharmacol 387:215-224.
37. Michel MC and BarendrechtMM(2008) Physiological and pathological regulation of the autonomic control of urinary bladder contractility. Pharmacol Ther 117:297-312.
38. Michel MC, Ochodnicky P, and Summers RJ (2010) Tissue functions mediated by b(3)-adrenoceptors-findings and challenges. Naunyn Schmiedebergs Arch Pharmacol 382:103-108.
39. Michel MC and Sand C (2009) Effect of pre-contraction on b-adrenoceptor-mediated relaxation of rat urinary bladder. World J Urol 27:711-715.
40. Michel MC, Teitsma CA, Vrydag W, Bontrop R, de la Rosette JJMCH, and Baas F (2008) β3-Adrenergic receptor gene polymorphisms: comparison of human with chimpanzee and Rhesus macaque. FASEB J 22:1134.3.
41. Michel MC and Vrydag W (2006) α1-, α2- and β -adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147 (Suppl 2):S88-S119.
42. Michel-Reher MB and Michel MC (2013) Agonist-induced desensitization of human β3-adrenoceptors expressed in human embryonic kidney cells. Naunyn Schmiedebergs Arch Pharmacol 386:843-851.
43. Mori A, Miwa T, Sakamoto K, Nakahara T, and Ishii K (2010) Pharmacological evidence for the presence of functional β (3)-adrenoceptors in rat retinal blood vessels. Naunyn Schmiedebergs Arch Pharmacol 382:119-126.
44. Muzzin P, Revelli J-P, Kuhne F, Gocayne JD, McCombie WR, Venter JC, Giacobino J-P, and Fraser CM (1991) An adipose tissue-specific b-adrenergic receptor. Molecular cloning and down-regulation in obesity. J Biol Chem 266:24053-24058.
45. Nahmias C, Blin N, Elalouf J-M, Mattei MG, Strosberg AD, and Emorine LJ (1991) Molecular characterization of the mouse β3-adrenergic receptor: relationship with the atypical receptor of adipocytes. EMBO J 10:3721-3727.
46. Nantel F, Bonin H, Emorine LJ, Zilberfarb V, Strosberg AD, Bouvier M, and Marullo S (1993) The human β3-adrenergic receptor is resistant to short term agonistpromoted desensitization. Mol Pharmacol 43:548-555.
47. Nergårdh A, Boréus LO, and Naglo AS (1977) Characterization of the adrenergic beta-receptor in the urinary bladder of man and cat. Acta Pharmacol Toxicol (Copenh) 40:14-21.
48. Ngala RA, O'Dowd JF, Stocker CJ, Cawthorne MA, and Arch JRS (2013) β2-adrenoceptor agonists can both stimulate and inhibit glucose uptake in mouse soleus muscle through ligand-directed signalling. Naunyn Schmiedebergs Arch Pharmacol 386:761-773.
49. Niclauß N, Michel-Reher MB, Alewijnse AE, and Michel MC (2006) Comparison of three radioligands for the labelling of human b-adrenoceptor subtypes. Naunyn Schmiedebergs Arch Pharmacol 374:99-105.
50. Ohlstein EH, von Keitz A, and Michel MC (2012) A multicenter, double-blind, randomized, placebo-controlled trial of the β3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol 62:834-840.
51. Pott C, Brixius K, Bundkirchen A, Bölck B, Bloch W, Steinritz D, Mehlhorn U, and Schwinger RHG (2003) The preferential β3-adrenoceptor agonist BRL 37344 increases force via β1-/β2-adrenoceptors and induces endothelial nitric oxide synthase via β3-adrenoceptors in human atrial myocardium. Br J Pharmacol 138: 521-529.
52. Rasmussen HH, Figtree GA, Krum H, and Bundgaard H (2009) The use of β3-adrenergic receptor agonists in the treatment of heart failure. Curr Opin Investig Drugs 10: 955-962.
53. Regard JB, Sato IT, and Coughlin SR (2008) Anatomical profiling of G proteincoupled receptor expression. Cell 135:561-571.
54. Reverte M, García-Barrado MJ, Hernández-García FJ, and Moratinos J (1993) Coexistence of b 2- and β3-adrenoceptors in plasma potassium control in conscious rabbits. J Auton Pharmacol 13:227-236.
55. Sato M, Horinouchi T, Hutchinson DS, Evans BA, and Summers RJ (2007) Liganddirected signaling at the beta3-adrenoceptor produced by 3-(2-Ethylphenoxy)-1-[(1, S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) relative to receptor agonists. Mol Pharmacol 74:1359-1368.
56. Sato M, Hutchinson DS, Evans BA, and Summers RJ (2008) The β3-adrenoceptor agonist 4-[[(Hexylamino)carbonyl]amino]-N-[4-[2-[[(2S)-2-hydroxy-3-(4-hydroxyphenoxy) propyl]amino]ethyl]-phenyl]-benzenesulfonamide (L755507) and antagonist (S)-N-[4- [2-[[3-[3-(acetamidomethyl)phenoxy]-2-hydroxypropyl]amino]-ethyl]phenyl] benzenesulfonamide (L748337) activate different signaling pathways in Chinese hamster ovary-K1 cells stably expressing the human β3-adrenoceptor. Mol Pharmacol 74: 1417-1428.
57. Sato M, Hutchinson DS, Halls ML, Furness SG, Bengtsson T, Evans BA, and Summers RJ (2012) Interaction with caveolin-1 modulates G protein coupling of mouse β3-adrenoceptor. J Biol Chem 287:20674-20688.
58. Scarpace PJ, Matheny M, and Tümer N (1999) Differential down-regulation of β3- adrenergic receptor mRNA and signal transduction by cold exposure in brown adipose tissue of young and senescent rats. Pflugers Arch 437:479-483.
59. Schneider T, Fetscher C, Krege S, and Michel MC (2004) Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 309:1148-1153.
60. Stemmelin J, Cohen C, Terranova J-P, Lopez-Grancha M, Pichat P, Bergis O, Decobert M, Santucci V, Françon D, and Alonso R et al. (2008) Stimulation of the β3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. Neuropsychopharmacology 33:574-587.
61. Takeda H, Yamazaki Y, Akahane M, Akahane S, Miyata H, Igawa Y, and Nishizawa O (2002) Characterization of β-adrenoceptor subtype in bladder smooth muscle in cynomolgus monkey. Jpn J Pharmacol 88:108-113.
62. Teitsma CA, de la Rosette JJMCH, and Michel MC (2013) Are polymorphisms of the β (3)-adrenoceptor gene associated with an altered bladder function? Neurourol Urodyn 32:276-280.
63. Thomas RF and Liggett SB (1993) Lack of β3-adrenergic receptor mRNA expression in adipose and other metabolic tissues in the adult human. Mol Pharmacol 43: 343-348.
64. van Wieringen JP, Michel-Reher MB, Hatanaka T, Ueshima K, and Michel MC (2013) The new radioligand [(3)H]-L 748,337 differentially labels human and rat β3- adrenoceptors. Eur J Pharmacol 720:124-130.
65. Vrydag W, Alewijnse AE, and Michel MC (2009) Do gene polymorphisms alone or in combination affect the function of human β3-adrenoceptors? Br J Pharmacol 156: 127-134.
66. Vrydag W and Michel MC (2007) Tools to study β3-adrenoceptors. Naunyn Schmiedebergs Arch Pharmacol 374:385-398.
67. Walston J, Silver K, Bogardus C, Knowler WC, Celi FS, Austin S, Manning B, Strosberg AD, Stern MP, and Raben N et al. (1995) Time of onset of non-insulindependent diabetes mellitus and genetic variation in the β3-adrenergic-receptor gene. N Engl J Med 333:343-347.